Our senior product manager, Ben Wylie, spoke to The Medicine Maker about how the COVID-19 pandemic highlighted the weaknesses in the globalised pharmaceutical supply chain, which led to many companies considering making the move to onshore their API supplies. Ben highlights both the benefits and downsides that companies are facing when making the decision to localise their supply, including how they are striking the balance between a more reliable supply chain with the potential of higher production costs that can come with more local suppliers. You can read the whole article here.
